2 papers indexed here
We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.
Not the right person? Other researchers publish under this name.
Introduction Brodalumab is the only interleukin-17 (IL-17) receptor A blocker approved for moderate-to-severe plaque psoriasis and blocks downstream signaling of multiple IL-17 isoforms including IL-17A, IL-17F, IL-17C, IL-17E, and IL-17A/F. Here, we contextualize effectiveness and safety of brodalumab in adult patient...
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.
